A Phase 3 Randomized Open-Label Three Arm Study of PF-06801591 in Combination with BCG (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with HR BCG-Na ve NMIBC (B8011006)

Brief description of study

The purpose of the study is to determine the safety and efficacy of PF-06801591 (an anti-PD-1 antibody) combined with Bacillus Calmette- Guerin (BCG) in patients with high-risk, BCG-naïve Non-Muscle Invasive Bladder Cancer (NMIBC). We want to know if the combined treatment of PF-06801591 and Bacillus Calmette- Guerin (BCG) works better than BCG alone.

Clinical Study Identifier: s19-01432
ClinicalTrials.gov Identifier: NCT04165317
Principal Investigator: Gary D. Steinberg.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.